A comparative profile of total protein and six angiogenically-active growth factors in three platelet products

Custo, Scott; Baron, Bruno; Felice, Alex E.; Seria, Elisa

doi:10.3205/iprs000167

Cited by 3 publications

(1 citation statement)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The bioavailability of EGF in the brain is ensured by production in glial cells and neurons and by uptake from the peripheral circulation [3], indicating that peripheral concentrations may be somewhat related to levels within the brain, but this is not described in detail yet. It may, of course, affect the interpretation of our results, especially since EGF is not specific to neural tissue and is found, for example, in the skin, salivary glands and platelets [40,41].…”

Section: Discussionmentioning

confidence: 98%

Sarcosine May Induce EGF Production or Inhibit the Decline in EGF Concentrations in Patients with Chronic Schizophrenia (Results of the PULSAR Study)

Pawlak,

Kaczmarek,

Wysokiński

et al. 2023

Pharmaceuticals

View full text Add to dashboard Cite

Sarcosine (N-methylglycine), a glutamatergic modulator, reduces the primary negative symptoms of schizophrenia. These beneficial changes might be mediated by trophic factors such as epidermal growth factor (EGF). We assessed associations between initial serum EGF levels or changes in serum EGF levels and symptom severity during the addition of sarcosine to stable antipsychotic treatment and thereby evaluated the associations between glutamatergic modulation, clinical changes and peripheral EGF concentrations. Fifty-eight subjects with a diagnosis of chronic schizophrenia with dominant negative symptoms, stably treated with antipsychotics, completed a prospective 6-month, randomized, double-blind, placebo-controlled study. Subjects received orally 2 g of sarcosine (n = 28) or placebo (n = 30) daily. Serum EGF levels and symptom severity (using the Positive and Negative Syndrome Scale (PANSS) and the Calgary Depression Scale for Schizophrenia (CDSS)) were assessed at baseline, 6-week and 6-month follow-up. Augmentation antipsychotic treatment with sarcosine had no effect on EGF serum levels at any time points. Only the sarcosine group showed a significant improvement in negative symptoms, general psychopathology subscales and the overall PANSS score. We found a reduction in serum EGF levels in the placebo group, but levels in the sarcosine remained stable during the study. Our data indicate that improvement in negative symptoms due to sarcosine augmentation is not directly mediated by EGF, but effective treatment may induce the production or block the decrease in EGF concentrations, which indicates the neuroprotective effect of treatment and confirms the relationship between neuroprotection and EGF levels.

show abstract

Section: Discussionmentioning

confidence: 98%

Sarcosine May Induce EGF Production or Inhibit the Decline in EGF Concentrations in Patients with Chronic Schizophrenia (Results of the PULSAR Study)

Pawlak,

Kaczmarek,

Wysokiński

et al. 2023

Pharmaceuticals

View full text Add to dashboard Cite

show abstract

Cord Blood as a Trophic-Growth Additive for Culture Work

Goncharov,

Shupletsova,

Gazatova

et al. 2024

Cell Tiss. Biol.

View full text Add to dashboard Cite

Sarcosine May Induce EGF Production or Inhibit the Decline in EGF Concentrations in Patients with Chronic Schizophrenia (Results of the PULSAR Study)

Pawlak,

Kaczmarek,

Wysokiński

et al. 2023

Preprint

View full text Add to dashboard Cite

Sarcosine (N-methylglycine), a glutamatergic modulator, reduces the primary negative symp-toms of schizophrenia. These beneficial changes might be mediated by trophic factors such as ep-idermal growth factor (EGF). We assessed associations between initial serum EGF levels or changes in serum EGF levels and symptom severity during the addition of sarcosine to stable an-tipsychotic treatment and thereby evaluate the associations between glutamatergic modulation, clinical changes and peripheral EGF concentrations. 58 subjects with a diagnosis of chronic schizophrenia with dominant negative symptoms, stably treated with antipsychotics completed a prospective 6-month, randomized, double-blind, placebo-controlled study. Subjects received orally 2 grams of sarcosine (n=28) or placebo (n=30) daily. Serum EGF levels and symptom se-verity (using Positive and Negative Syndrome Scale - PANSS and Calgary Depression Scale for Schizophrenia - CDSS) were assessed at baseline, 6 weeks, and 6 months follow-up. Augmenta-tion antipsychotic treatment with sarcosine had no effect on EGF serum levels at any time-points. Only the sarcosine group showed a significant improvement in negative symptoms, general psy-chopathology subscales, and the overall PANSS score. We found reduction of serum EGF levels in the placebo group, but levels in the sarcosine remained stable during the study. Our data indicate that improvement in negative symptoms due to sarcosine augmentation is not mediated by EGF, but effective treatment may induce the production or block the decrease in EGF concentrations, which indicates the neuroprotective effect of treatment and confirms the relationship between neuroprotection and EGF levels.

show abstract

A comparative profile of total protein and six angiogenically-active growth factors in three platelet products

Cited by 3 publications

References 39 publications

Sarcosine May Induce EGF Production or Inhibit the Decline in EGF Concentrations in Patients with Chronic Schizophrenia (Results of the PULSAR Study)

Sarcosine May Induce EGF Production or Inhibit the Decline in EGF Concentrations in Patients with Chronic Schizophrenia (Results of the PULSAR Study)

Cord Blood as a Trophic-Growth Additive for Culture Work

Sarcosine May Induce EGF Production or Inhibit the Decline in EGF Concentrations in Patients with Chronic Schizophrenia (Results of the PULSAR Study)

Contact Info

Product

Resources

About